The role of statins in the treatment of the metabolic syndrome

Current Hypertension Reports

Volumn 11, Issue 2, 2009, Pages 143-149

  Ott, Christian ^a   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN;

ABDOMINAL OBESITY; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DYSLIPIDEMIA; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; HEREDITY; HIGH RISK PATIENT; HUMAN; INFLAMMATION; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MICROALBUMINURIA; NONALCOHOLIC FATTY LIVER; PHYSICAL ACTIVITY; PLEIOTROPY; POST HOC ANALYSIS; PREVALENCE; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; VASCULAR ENDOTHELIUM; WEIGHT REDUCTION;

ADULT; AGED; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; METABOLIC SYNDROME X; MIDDLE AGED; TREATMENT OUTCOME;

EID: 62549153138     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-009-0025-6     Document Type: Review

References (51)

1. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
2. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a who consultation. Diabet Med 1998, 15:539-553.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
4. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome - a new worldwide definition. Lancet 2005, 366:1059-1062.
5. Grundy SM: Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008, 28:629-636.
6. Wilson PW, D'Agostino RB, Parise H, et al.: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112:3066-3072.
7. Gami AS, Witt BJ, Howard DE, et al.: Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007, 49:403-414.
8. Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: An American heart association/national heart, lung, and blood institute scientific statement. Circulation 2005, 112:2735-2752.
9. Grundy SM: MetAbolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007, 92:399-404.
10. Cannon CP, Steinberg BA, Murphy SA, et al.: Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006, 48:438-445.
11. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
12. Clearfield M, Downs JR, Lee M, et al.: Implications from the Air Force/ Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines. Am J Cardiol 2005, 96:1674-1680.
13. Sattar N, Gaw A, Scherbakova O, et al.: Metabolic syndrome with and without c-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study. Circulation 2003, 108:414-419.
14. Pyorala K, Ballantyne CM, Gumbiner B, et al.: Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: Subgroup analyses of the Scandinavian simvastatin survival study (4s). Diabetes Care 2004, 27:1735-1740.
15. Deedwania P, Barter P, Carmena R, et al.: Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the treating to new targets study. Lancet 2006, 368:919-928.
16. Sasaki S, Kuwahara N, Kunitomo K, et al.: Effects of atorvastatin on oxidized low-density lipoprotein, lowdensity lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 2002, 89:386-389.
17. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712-1719.
18. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
19. Ridker PM, Rifai N, Rose L, et al.: Comparison of c-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
20. TrayhuIn P, Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004, 92:347-355.
21. Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
22. Gustafson B, Hammarstedt A, Andersson CX, Smith U: Inflamed adipose tissue: A culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:2276-2283.
23. Mora S, Ridker PM: Justification for the use of statins in primary prevention: An intervention trial evaluating rosuvastatin (JUPITER)-can c-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 2006, 97:33A-41A.
24. Ridker PM, Wilson PW, Grundy SM: Should c-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004, 109:2818-2825.
25. Devaraj S, Chan E, Jialal I: Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 2006, 91:4489-4496.
26. Singh U, Devaraj S, Jialal I, Siegel D: Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol 2008, 102:321-325.
27. Balk EM, Lau J, Goudas LC, et al.: Effects of statins on nonlipid serum markers associated with cardiovascular disease: A systematic review. Ann Intern Med 2003, 139:670-682.
28. Kinlay S: Low-density lipoprotein-dependent and - independent effects of cholesterol-lowering therapies on c-reactive protein: A meta-analysis. J Am Coll Cardiol 2007, 49:2003-2009.
29. Vane JR, Anggard EE, Botting RM: Regulatory functions of the vascular endothelium. N Engl J Med 1990, 323:27-36.
30. Govers R, Rabelink TJ: Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2001, 280:F193-206.
31. Werns SW, Walton JA, Hsia HH, et al.: Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 1989, 79:287-291.
32. Koh KK, Han SH, Quon MJ: Inflammatory markers and the metabolic syndrome: Insights from therapeutic interventions. J Am Coll Cardiol 2005, 46:1978-1985.
33. Wolfrum S, Jensen KS, Liao JK: Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003, 23:729-736.
34. John S, Schlaich M, Langenfeld M, et al.: Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: A randomized, placebo-controlled, double-blind study. Circulation 1998, 98:211-216.
35. Perticone F, Ceravolo R, Maio R, et al.: Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients. Atherosclerosis 2000, 152:511-518.
36. John S, Schneider MP, Delles C, et al.: Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005, 149:473.
37. Ott C, Schlaich MP, Schmidt BM, et al.: Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis 2008, 196:704-711.
38. Oguz A, Uzunlulu M: Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. Int Heart J 2008, 49:303-311.
39. Anderson TJ: Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999, 34:631-638.
40. Chen J, Muntner P, Hamm LL, et al.: The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004, 140:167-174.
41. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al.: Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. Nephrol Dial Transplant 2007, 22:118-127.
42. Geluk CA, Asselbergs FW, Hillege HL, et al.: Impact of statins in microalbuminuric subjects with the metabolic syndrome: A substudy of the prevend intervention trial. Eur Heart J 2005, 26:1314-1320.
43. de Zeeuw D: Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int Suppl 2004:S2-S6.
44. Hillege HL, Fidler V, Diercks GF, et al.: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002, 106:1777-1782.
45. Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003, 37:1202-1219.
46. Hamaguchi M, Kojima T, Takeda N, et al.: The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005, 143:722-728.
47. Athyros VG, Mikhailidis DP, Didangelos TP, et al.: Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: A randomised study. Curr Med Res Opin 2006, 22:873-883.
48. Argo CK, Loria P, CaAdwell SH, Lonardo A: Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 2008, 48:662-669.
49. Lewis JH, Mortensen ME, Zweig S, et al.: Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007, 46:1453-1463.
50. Ekstedt M, Franzen LE, Mathiesen UL, et al.: Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study. J Hepatol 2007, 47:135-141.
51. Grundy SM: Cardiovascular and metabolHc risk factors: how can we improve outcomes in the high-risk patient? Am J Med 2007, 120(9 Suppl 1):S3-S8.